{"organizations": [], "uuid": "6c8f06143ad3b1f1db695eb3ec2943efa26a9b29", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-biophytis-updates-on-sara-clinical/brief-biophytis-updates-on-sara-clinical-study-of-sarconeos-in-sarcopenia-idUSFWN1QJ0B7", "country": "US", "domain_rank": 408, "title": "Biophytis Updates On Sara Clinical Study Of Sarconeos In Sarcopenia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-03-01T15:06:00.000+02:00", "replies_count": 0, "uuid": "6c8f06143ad3b1f1db695eb3ec2943efa26a9b29"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-biophytis-updates-on-sara-clinical/brief-biophytis-updates-on-sara-clinical-study-of-sarconeos-in-sarcopenia-idUSFWN1QJ0B7", "ord_in_thread": 0, "title": "Biophytis Updates On Sara Clinical Study Of Sarconeos In Sarcopenia", "locations": [], "entities": {"persons": [{"name": "biophytis", "sentiment": "negative"}], "locations": [{"name": "sarcopenia", "sentiment": "none"}, {"name": "sarcope", "sentiment": "none"}, {"name": "sarcopenia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - BIOPHYTIS SA:\n* BIOPHYTIS UPDATES ON SARA CLINICAL STUDY OF SARCONEOS IN SARCOPENIA\n* THESE RESULTS DEMONSTRATE THE STRONG POTENTIAL OF SARCONEOS (BIO101) IN THE TREATMENT OF SARCOPENIA\n* THESE RESULTS CONFIRM THE RELEVANCE OF THE SARA-INTEREST INTERNATIONAL CLINICAL STUDY\n* FIRST PATIENT WILL BE ENROLLED IN THE COMING WEEKS * FIRST PATIENT IN CLINICAL STUDY WILL BE ENROLLED IN THE COMING WEEKS Source text : reut.rs/2ozc0LY (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://reut.rs/2ozc0LY"], "published": "2018-03-01T15:06:00.000+02:00", "crawled": "2018-03-02T20:24:30.021+02:00", "highlightTitle": ""}